The reiteration of an Outperform rating and the maintenance of a $8 price target by a reputable analyst like Gregory Renza from RBC Capital could instill confidence among investors and potentially lead to a positive short term impact on ADC Therapeutics' stock price. Analyst ratings and price targets are significant indicators for investors, and a positive outlook from a well-regarded financial institution can influence market perception and investor sentiment towards the stock.